1. Home /
  2. Biotechnology

Biotechnology

Voyager Shares Take Off on Parkinson's Disease Development Deal

Voyager Shares Take Off on Parkinson's Disease Development Deal

AbbVie to provide multi-million-dollar financing to Voyager to develop and commercialize potential Parkinson's treatment.

Bausch Health Swings to Loss but Revenue Tops Analysts' Expectations

Bausch Health Swings to Loss but Revenue Tops Analysts' Expectations

Bausch Health swings to a loss in the fourth quarter but issues positive revenue guidance for fiscal 2019.

3 Small Biotechs to Watch as Earnings Season Winds Down

3 Small Biotechs to Watch as Earnings Season Winds Down

One already is up nicely on its results, while the other two should issue reports of interest in the next few days.

Medtronic Reports Strong Surgical Product Sales on Way to Earnings Beat

Medtronic Reports Strong Surgical Product Sales on Way to Earnings Beat

Medtronic raises its full-year earnings forecast above analysts' estimates.

Behind the Cutting Edge Technology: The History of Amgen

Behind the Cutting Edge Technology: The History of Amgen

This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Moderna's Small Base Could Surprise on the Upside

Moderna's Small Base Could Surprise on the Upside

Prices have moved above the early January high giving us the simple definition of an uptrend.

Incyte Expected to Earn 17 Cents a Share

Incyte Expected to Earn 17 Cents a Share

Incyte revenue expected to rise 9.5% to $486.2 million.

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.

It's a Stock Picker's Delight Right Now

It's a Stock Picker's Delight Right Now

With cash levels high, those players who are not well-positioned for upside action are scrambling to put money to work and are helping to propel prices higher.